Invex Therapeutics (ASX:IXC) Common Stock: A$22.41 Mil (As of Dec. 2025)


What is Invex Therapeutics Common Stock?

Invex Therapeutics ASX:IXC -9.09% Common Stock is A$22.41 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's quarterly common stock stayed the same from Dec. 2024 (A$22.41 Mil) to Jun. 2025 (A$22.41 Mil) and stayed the same from Jun. 2025 (A$22.41 Mil) to Dec. 2025 (A$22.41 Mil).

Invex Therapeutics's annual common stock declined from Jun. 2023 (A$36.41 Mil) to Jun. 2024 (A$22.41 Mil) but then stayed the same from Jun. 2024 (A$22.41 Mil) to Jun. 2025 (A$22.41 Mil).

Invex Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Common Stock Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial 36.41 36.41 36.41 22.41 22.41

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.41 22.41 22.41 22.41 22.41

Invex Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$22.41 Mil mean?
Invex Therapeutics (ASX:IXC) has a Common Stock of A$22.41 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Common Stock too high?
Invex Therapeutics' current Common Stock is A$22.41 Mil.
How does Invex Therapeutics' Common Stock compare to VRTX and REGN?
Invex Therapeutics' Common Stock of A$22.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Common Stock is A$22.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Common Stock of A$22.41 Mil. The current Common Stock is A$22.41 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Common Stock is A$22.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.